COVID-19 and Cardiovascular Disease

Author:

Clerkin Kevin J.1,Fried Justin A.1,Raikhelkar Jayant1,Sayer Gabriel1,Griffin Jan M.1,Masoumi Amirali1,Jain Sneha S.1,Burkhoff Daniel1,Kumaraiah Deepa1,Rabbani LeRoy1,Schwartz Allan1,Uriel Nir1

Affiliation:

1. Department of Medicine, Division of Cardiology, Columbia University Vagelos College of Physicians and Surgeons, New York.

Abstract

Coronavirus disease 2019 (COVID-19) is a global pandemic affecting 185 countries and >3 000 000 patients worldwide as of April 28, 2020. COVID-19 is caused by severe acute respiratory syndrome coronavirus 2, which invades cells through the angiotensin-converting enzyme 2 receptor. Among patients with COVID-19, there is a high prevalence of cardiovascular disease, and >7% of patients experience myocardial injury from the infection (22% of critically ill patients). Although angiotensin-converting enzyme 2 serves as the portal for infection, the role of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers requires further investigation. COVID-19 poses a challenge for heart transplantation, affecting donor selection, immunosuppression, and posttransplant management. There are a number of promising therapies under active investigation to treat and prevent COVID-19.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Physiology (medical),Cardiology and Cardiovascular Medicine

Reference68 articles.

1. An interactive web-based dashboard to track COVID-19 in real time [published online February 19, 2020].;Dong E;Lancet Infect Dis

2. Short term outcome and risk factors for adverse clinical outcomes in adults with severe acute respiratory syndrome (SARS)

3. Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis

4. The proximal origin of SARS-CoV-2 [published online March 17, 2020].;Andersen KG;Nat Med

5. Probable pangolin origin of SARS-CoV-2 associated with the COVID-19 outbreak [published online March 13, 2020].;Zhang T;Curr Biol

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3